CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices

Year End: December

GICS Industry Group : Health Care Equipment & Services

Debt/EBITDA: -0.68

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$2.05 26 May 2023	0.000 OPEN $2.09	0.000 HIGH $2.11	22,983 LOW $2.05

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$2.05

26 May
2023

0.000

OPEN

$2.09

0.000

HIGH

$2.11

22,983

LOW

$2.05

TARGET

$2.80

36.6% upside

Franking for last dividend paid out: 0%

OTHER COMPANIES IN THE SAME SECTOR
4DX . AHZ . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . EBR . ELX . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . LHC . MEB . MX1 . NAN . ONE . OVN . PCK . PEB . PGC . PME . RAP . RMD . RVA . SOM . TRJ . UBI . VHT . VTI .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY21 Actual	FY22 Actual	FY23 Forecast	FY24 Forecast
EPS (cps)	xxx	- 7.2	- 6.5	xxx
DPS (cps)	xxx	N/A	1.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	N/A	xxx
Dividend Yield	xxx	N/A	0.5%	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2023 FactSet UK Limited. All rights reserved

Title	2017	2018	2019	2020	2021	2022
EPS Basic	xxx	xxx	xxx	xxx	xxx	-7.2
DPS All	xxx	xxx	xxx	xxx	xxx	1.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	23.2 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	39.3
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-6.7 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-28.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2017	2018	2019	2020	2021	2022
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-16.61 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-15.02 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-12.56 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-16.61 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-16.46 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2017	2018	2019	2020	2021	2022
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	4 M
Total Debt	xxx	xxx	xxx	xxx	xxx	4 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	20 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	2.98

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2017	2018	2019	2020	2021	2022
Capex	xxx	xxx	xxx	xxx	xxx	1.5 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	6.67 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	17 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	13 M
Research & Development	xxx	xxx	xxx	xxx	xxx	3 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Bell Potter	26/04/2023	1	Upgrade to Buy from Hold	$2.80	36.59%	The US Federal Drug Administration (FDA) has advised Cyclopharm that its response is complete and that the company will be eligible for review; and has set a potential approval date of September 29, 2023. Bell Potter estimates the market for Cyclopharm's Technegas at US$180m. The broker sounds miffed about the last approval delay, which the FDA claimed was based on a lack of safety and efficacy data, while Cyclopharm pointed out that the Complete Response Letter did not relate to such, not to mention the tens of thousands of doses already being delivered to patients outside the US each year, says the broker. Meanwhile, Bell Potter claims the nuclear medicine community in the US is champing at the bit to get started and observes the company is well capitalised to start the launch. Rating upgraded to Buy from Hold. Target price rises to $2.80 from $1.70. FORECAST Bell Potter forecasts a full year FY23 dividend of 1.00 cents and EPS of minus -6.50 cents. Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of 3.20 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Bell Potter

26/04/2023

Upgrade to Buy from Hold

$2.80

36.59%

The US Federal Drug Administration (FDA) has advised Cyclopharm that its response is complete and that the company will be eligible for review; and has set a potential approval date of September 29, 2023.

Bell Potter estimates the market for Cyclopharm's Technegas at US$180m. The broker sounds miffed about the last approval delay, which the FDA claimed was based on a lack of safety and efficacy data, while Cyclopharm pointed out that the Complete Response Letter did not relate to such, not to mention the tens of thousands of doses already being delivered to patients outside the US each year, says the broker.

Meanwhile, Bell Potter claims the nuclear medicine community in the US is champing at the bit to get started and observes the company is well capitalised to start the launch.

Rating upgraded to Buy from Hold. Target price rises to $2.80 from $1.70.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 1.00 cents and EPS of minus -6.50 cents.
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of 3.20 cents.

Access Stockbroker Research History >

CYC STOCK CHART

FNArena News on CYC

1	Weekly Ratings, Targets, Forecast Changes – 28-04-23 May 01 2023 - Weekly Reports

2	Australian Broker Call Extra Edition – Mar 06, 2023 Mar 06 2023 - Daily Market Reports

3	Australian Broker Call Extra Edition – Jul 21, 2022 Jul 21 2022 - Daily Market Reports

4	Australian Broker Call Extra Edition – May 19, 2022 May 19 2022 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 23, 2021 Sep 23 2021 - Daily Market Reports

Latest Medical Equipment & Devices News

1	Dr Boreham’s Crucible: Impedimed May 08 2023 - Small Caps

2	Treasure Chest: ResMed’s Benevolent Monopoly May 01 2023 - Treasure Chest

3	Dr Boreham’s Crucible: Volpara Health Technologies Apr 26 2023 - Small Caps

4	Dr Boreham’s Crucible: SDI Mar 16 2023 - Small Caps

5	Dr Boreham’s Crucible: Cochlear Mar 03 2023 - Australia

6	Dr Boreham’s Crucible: Imagion Biosystems Feb 13 2023 - Small Caps

7	ResMed: Philips Remains The Big Unknown Jan 31 2023 - Australia

8	Nanosonics Outlook Remains Clouded Jan 24 2023 - Small Caps

9	Nanosonics Recovers On Less Negative Sentiment Nov 29 2022 - Small Caps

10	Treasure Chest: Fisher & Paykel Healthcare Nov 16 2022 - Treasure Chest

Dividend Yield Today On Last Actual Payout :	N/A
Estimated Dividend Growth (Average Of Past Three Years)
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

1	Weekly Ratings, Targets, Forecast Changes – 28-04-23 May 01 2023 - Weekly Reports

2	Australian Broker Call Extra Edition – Mar 06, 2023 Mar 06 2023 - Daily Market Reports

3	Australian Broker Call Extra Edition – Jul 21, 2022 Jul 21 2022 - Daily Market Reports

4	Australian Broker Call Extra Edition – May 19, 2022 May 19 2022 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 23, 2021 Sep 23 2021 - Daily Market Reports

Get 2 Weeks free trial

Sign Up

Member Login

CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart